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A 77-year-old man, former smoker, followed for idiopathic
pulmonary fibrosis (IPF) presented with right side chest
pain. Chest X-rays showed a right pulmonary mass of the
lower lobe (absent the year before), and high-resolution
computed tomography (HRCT) imaging confirmed the
presence of a right lung mass (maximum diameter
65 9 32 mm) with relatively irregular margins in a diffuse
infiltrative fibrotic interstitial disease (Fig. 1a, b) with
radiological ‘‘UIP pattern’’ according to the official 2011
ATS/ERS/JRS/ALAT guidelines [1]. The lung mass
showed intensive uptake of the radio-tracer at 18F-FDG
PET/CT-scan (SUVmax = 25) with no other areas of
uptake (Fig. 1c, d).
A CT-scan-guided percutaneous biopsy revealed large
areas of cartilage with cell atypia (Fig. 2a, b) and a spindle-
shaped neoplastic cell proliferation weakly expressing pan-
cytokeratins (clone AE1/AE3) and p63 (Fig. 2c, d), but
negative with TTF1. A tentative diagnosis of sarcomatoid
carcinoma (SC) with heterologous chondrosarcomatous
component (namely carcinosarcoma) was made. Despite
the high comorbidity and the dismal long-term prognosis
related to IPF, but considering the early-stage of the lung
cancer (cT2N0M0) and the patient’s will, a multidisci-
plinary oncologic team recommended surgical removal and
the patient underwent right lower lobectomy. The final
pathological diagnosis of carcinosarcoma (stage pT2bN0)
arising in the framework of IPF was made. A multiplex
molecular analysis (Sequenom, MassARRAY Analyzer 4,
Diatech Pharmacogenetics, Jesi, Italy) showed no gene
alterations. The post-operative course was uneventful and
the patient is still alive without relapse 3 months after
surgery.
Carcinosarcoma is an extremely uncommon variant of
lung cancer belonging to the rubric of sarcomatoid carci-
noma (according to the last 2015 WHO classification [2]).
It usually runs an aggressive clinical course, with poorer
prognosis, higher metastatic potential than other non-small-
cell lung carcinomas (NSCLC) and very limited respon-
siveness to standard drugs [3]. On the other hand, IPF is the
most severe idiopathic interstitial pneumonia, with typical
HRCT features and histologic pattern of usual interstitial
pneumonia (UIP).
Despite that the epithelial-to-mesenchymal transition
(EMT) has been supposed to be the key pathway strongly
involved in both the pathogenesis of IPF and SC [3, 4],
contrary to other conventional lung cancer histotypes
(e.g., adenocarcinoma, squamous cell carcinoma, large-
cell and small-cell carcinoma) [5], carcinosarcoma has
never been reported in association with IPF. Treating
patients with both SC and IPF is a real challenge con-
sidering the dismal prognosis of both diseases and the
high morbidity and mortality rate after pulmonary resec-
tion [5].
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Fig. 1 Radiological evaluation
of the right pulmonary mass in
the framework of an interstitial
lung disease (a, b); significant
uptake (SUVmax = 25) of the
mass at 18F-FDG PET/CT scan
Fig. 2 Pathological evaluation
of the percutaneous biopsy
revealed a mixture of large areas
of cartilage with cell atypia (a,
b) and a spindle-shaped
neoplastic cell proliferation
weakly expressing pan-
cytokeratins (c) and p63 (d)
Lung
123
Acknowledgments The authors thank Dr. Cavazza Alberto (expert
pulmonary pathologist) for his precious contribution (‘‘confirmatory
opinion’’).
Author Contributions All authors contributed to patient care and
wrote the report. Written consent to publication was obtained.
Compliance with Ethical Standards
Conflict of interest None.
References
1. Raghu G, Collard HR, Egan JJ et al (2011) An official ATS/ERS/
JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-
based guidelines for diagnosis and management. Am J Respir Crit
Care Med 183:788–824
2. Travis WD, Brambilla E, Burke AP et al (2015) WHO classifi-
cation of tumours of the lung, pleura, thymus and heart. IARC
Press, Lyon, pp 78–79
3. Lin Y, Yang H, Cai Q et al (2014) Characteristics and prognostic
analysis of 69 patients with pulmonary sarcomatoid carcinoma.
Am J Clin Oncol. doi:10.1097/COC.0000000000000101
4. Rossi G, Cavazza A, Sturm N et al (2003) Pulmonary carcinomas
with pleomorphic, sarcomatoid, or sarcomatous elements: a
clinicopathologic and immunohistochemical study of 75 cases.
Am J Surg Pathol 27(3):311–324
5. Kawasaki H, Nagai K, Yoshida J et al (2002) Postoperative
morbidity, mortality, and survival in lung cancer associated with
idiopathic pulmonary fibrosis. J Surg Oncol 81(1):33–37
Lung
123
